A multicentre, Phase II, single-arm, interventional study of neoadjuvant durvalumab and platinum-based chemotherapy (CT), followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab, in participants with resectable or borderline resectable stage IIB-IIIB Non-small Cell Lung Cancer (NSCLC).
Fase: Phase II-III clinical trials
Struttura Principale: Oncologia Medica Toraco-Polmonare
Farmaco: Durvalumab (a type of anti-cancer drug called immunotherapy).
Standard chemotherapy treatment (SoC): pemetrexed/cisplatin or pemetrexed/carboplatin.
If the tumour is unresectable, it will receive SoC radiotherapy.
Patologie: Lung cancer
ClinicalTrials.gov: Read the details about clinical trials
PI: Dr Claudia Proto
The purpose of this study is to assess efficacy and safety of neoadjuvant durvalumab in combination with platinum-based chemotherapy (CT) given as initial therapy after cancer diagnosis followed by either surgery and adjuvant durvalumab or chemoradiotherapy (CRT) and consolidation durvalumab given alone as further therapy in participants with resectable and borderline resectable stage IIB-IIIB NSCLC.
The study will consist of the following five periods: screening period, initial treatment period, main treatment period for participants with resectable tumours (surgery) or unresectable tumours (chemoradiation therapy), final treatment period and follow-up period.
Last update: 20/05/2025